New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
11:15 EDTOVTI, INCY, CONN, VEEV, GES, BIG, GDP, KKD, DLLR, ANFOptions with decreasing implied volatility
Options with decreasing implied volatility: GDP CONN ANF BIG INCY DLLR GES OVTI KKD VEEV
News For GDP;CONN;ANF;BIG;INCY;DLLR;GES;OVTI;KKD;VEEV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2016
11:54 EDTGESGuess to implement program to eliminate angora fiber
The company noted, "During 2015, while developing our sustainability practices and publishing our first sustainability report, GUESS evaluated our practices related to the use of angora fibers. As a result of this process, GUESS is implementing a program to eliminate angora fiber from our future collections available in retail stores worldwide." GUESS CEO, Victor Herrero stated, "While in the past, GUESS has worked to ensure the minimal amount of angora used was ethically sourced, we feel the decision to eliminate angora moving forward is just the right thing to do."
10:05 EDTGESGuess says angora fiber 'should not be used' in production of any product
Guess?, Inc. announces that during 2015, while developing our sustainability practices and publishing its first sustainability report, it evaluated our policy related to the use of angora fiber. The company comments: "Effective immediately, angora fiber should not be used in the production of any product going forward or contained in any private label products. This pertains to promotional items as well."
January 28, 2016
11:33 EDTINCYOptions with increasing call volume
Subscribe for More Information
08:14 EDTINCYIncyte selloff brings long-term buying opportunity, says Jefferies
Subscribe for More Information
08:08 EDTINCYIncyte selloff a buying opportunity, says Leerink
Leerink analyst Michael Schmidt recommends using today's pullback in shares of Incyte after the company announced its decision to stop one arm of its ongoing Phase II trial of ruxolitinib in metastatic colorectal cancer due to futility as a buying opportunity. The study is one of several ongoing trials to evaluate ruxolitinib in various solid tumor indications, the analyst points out. He says that while the news is disappointing, the stock's current valuation reflects very little if any value for ruxolitinib in solid tumor indications. Schmidt lowered his price target for Incyte shares to $118 from $135 and reiterates an Outperform rating on the name. The stock is down 13%, or $9.98, to $65.01 in pre-market trading.
07:43 EDTINCYIncyte weakness creates buying opportunity, says Oppenheimer
After Incyte announced that it would stop a Phase-2 study of Ruxolitinib plus regorafenib for R/R metastatic colorectal cancer and high-CRP patients due to insufficient efficacy, Oppenheimer says the data makes the drug's anti-inflammatory properties in solid tumors questionable. However, the firm did not previously include revenue from the drug outside of pancreatic cancer in its estimates. The firm keeps a $129 price target and Outperform rating on the shares.
January 27, 2016
19:30 EDTINCYOn The Fly: After Hours Movers
UP AFTER EARNINGS: Facebook (FB), up 11.4%... Mellanox (MLNX), up 6.4%... Paypal (PYPL), up 5%... Crown Castle (CCI), up 2.2%... Citrix (CTXS), up 2.4%... Las Vegas Sands (LVS), up 1%... SanDisk (SNDK), up 1%. ALSO HIGHER: Radius Health (RDUS), up 1.2% after announcing a clinical collaboration with Novartis (NVS)... LinkedIn (LNKD) is up 2.4%, Alphabet (GOOG, GOOGL) is up 2.2% and 2.6%, respectively, Netflix (NFLX) is up 1%, Amazon.com (AMZN) is up 2%, and Twitter (TWTR) is up marginally after Facebook reported quarterly results... MGM Resorts (MGM) is up 2.2% and Wynn Resorts (WYNN) is up 2.2%. DOWN AFTER EARNINGS: ServiceNow (NOW), down 16.5%... eBay (EBAY), down 12.8%... United Rentals (URI), down 9.7%... Juniper Networks (JNPR), down 9.6%... Silicon Graphics (SGI), down 9.1%... Discover Financial (DFS), down 7.4%... InvenSense (INVN), down 6.1%... Core Laboratories (CLB), down 4.3%... Vertex Pharmaceuticals (VRTX), down 1.1%. ALSO LOWER: Incyte (INCY), down 12.8% after announcing that it will halt the Phase 2 sub-study of ruxolitinib or placebo in combination with regorafenib after a planned interim analysis of the high CRP subgroup demonstrated that ruxolitinib plus regorafenib did not show a sufficient level of efficacy to warrant continuation.
16:45 EDTINCYIncyte to stop Phase 2 sub-study of ruxolitinib plus regorafenib
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use